Immune reconstitution inflammatory syndrome or IRIS;Syndrome inflammatoire de reconstitution immune

Medecine/Sciences

Volumn 26, Issue 3, 2010, Pages 281-289

  Breton, Guillaume ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORYNEBACTERINEAE; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM;

ANTIRETROVIRUS AGENT;

AUTOIMMUNE DISEASE; DELAYED HYPERSENSITIVITY; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; IRIS DISEASE; REVIEW;

ANTI-RETROVIRAL AGENTS; AUTOIMMUNE DISEASES; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSION; INFLAMMATION; IRIS DISEASES; POLYMORPHISM, GENETIC; TRANSPLANTATION IMMUNOLOGY;

EID: 77953117253     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2010263281     Document Type: Review

References (42)

1. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-27.
2. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213-27.
3. French MA. Immune reconstitution inflammatory syndrome: a reapparaisal. Clin Infect Dis 2009; 48: 101-7.
4. Chen VCC, Yuen KY, Wong SSY, et al. Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 2001; 20: 402-6.
5. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40: 1756-61.
6. Micelli MH, Maertens J, Buvé K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-20.
7. Garcia-Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-9.
8. Singh N, Perfect Jr. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007; 45: 1192-9.
9. Breton G. Syndrome de reconstitution immunitaire chez les patients infectés par le VIH. La Lettre de l'Infectiologue 2006; 3: 116-25.
10. Meintjes G, Lawn S, Scanio F, et al. For the international network for the study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definition for use in resourcelimited settings. Lancet Infect Dis 2008; 8: 516-23.
11. Haddow LJ, Moosa MY, Easterbrook PJ. Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 103-8.
12. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61.
13. Breton G. Immune reconstitution inflammatory syndrome. In: Schaaf SH, Zumla A, eds. Tuberculosis: a comprehensive clinical reference. New York: Saunders-Elsevier, 2009; 689-700.
14. Lortholary O, Fontanet A, Némain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS 2005; 19: 1043-9.
15. Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20: 119-21.
16. Legrand F, Lecuit M Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46: 696-702.
17. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20: F 1-7.
18. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lympadenitis and cryptococcal meningitis. HIV Med 2008; 9: 307-16.
19. Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005; 80: 1131-3.
20. Seddiki N, Sasson SC, Santaner-Nanan B, et al. Proliferation of weakly suppressive regulatory CD4 T cells is associated with over-active CD4 T cell response in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009; 39: 391-403.
21. Bourgarit A, Carcelain G, Samri A, et al. TB-associated immune restoration syndrome in HIV-1-infected patients involves tuberculinspecific CD4Th1 cells and can be predicted by KIR-negative gd T cells. Montreal: 16th Conference on retroviruses and opportunistic infections, 2009 (abstract 772).
22. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16: 2043-7.
23. Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109: 449-55.
24. Egli A, Bergamin O, Müllhaupt B, et al. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis 2008; 10: 27-43.
25. Bochud PY, Hawn TR, Siddiqui MR, et al. Toll-like receptor 2 polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008; 197: 253-61.
26. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-41.
27. Manabe YC, Cambell JD, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46: 456-62.
28. Murdoch DM, Venter WDF, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in south Africa: a prospective study. AIDS 2008; 22: 601-10.
29. Cheng VCC, Yam WC, Woo PCY, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003; 22: 597-602.
30. Azoulay E, Darmon M, Delchaux C, et al. Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 2002; 30: 781-6.
31. Shelburne SA, Visnegarwala F, Darcourt, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during higly active antiretroviral therapy. AIDS 2005; 19: 399-406.
32. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-12.
33. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of HAART-induced immune reconstitution on development and outcome of progressive multifocal encephalopathy: study of 43 cases with review of the litterature. J Neurovirol 2003; 9: 73-80.
34. Tan K, Roda R, Ostrow L, Mc Arthur J, Nath A. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009; 72: 1458-64.
35. Cheng VCC, Ho PL, Lee RA, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21: 803-9.
36. Cheng VCC, Woo PCY, Lau SKP, et al. Peripartum tuberculosis as a form of immunorestitution disease. Eur J Clin Microb Infect Dis 2003; 22: 313-7.
37. Park WB, Choe PG, Jo JH, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long term outcome. AIDS 2006; 20: 2390-2.
38. Kaplan JE, Benson C, Homes KK, Brooks JT, Masur TT. Guidelines for prevention and treatment of opportunistics infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep (MMWR) 2009; 58: 1-198.
39. Meintjes G, Wilkinson R, Morroni C, et al. Randomiszed placebo-controlled trial of prednisone for the TB IRIS. Montreal: 16th Conference on retroviruses and opportunistic infections, 2009 (abstract 34).
40. Zolopa A, Anderson J, Komarow L, et al. Immediate versus deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG 5164. Boston: 15th Conference on retroviruses and opportunistic infections, 2008 (abstract 142).
41. Catros V, Bouet F, Cabillic F, et al. Lymphocytes T gamma delta en cancérologie: des lymphocytes tueurs non conventionnels. Med Sci (Paris) 2010; 26: 185-93.
42. Leung-Theung-Long S, Guerder S. Les cellules Th17: une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008; 24: 972-6.